Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study - Swain, SM; Miles, D; Kim, SB (Lancet Oncol, 2020)
et al.